Artificial Intelligence (AI) has taken the lead in technological advancement across the pharmaceutical sector. It is expected to transform pre-clinical drug discovery through reducing costs by up to 40% and creating a market worth up to $50 billion in the next decade.
Are you ready for this transformative period?
Hear first-hand the latest AI advancements across the pharmaceutical sector directly from experts in the field and obtain strategies to support your operations at the highly anticipated AI in Drug Discovery conference.
Driven by a move towards personalised therapies and novel drug candidates, Artificial Intelligence (AI) has taken the lead in technological advancement across the pharmaceutical sector. Increased efficiency of the drug discovery process, through innovations including automation, in-silico modelling, and machine learning, accelerate growth in an ever-expanding field, focused on revolutionising modern healthcare.
2024 European Conference Speakers Included
- Daniel Cohen, President, Valence Labs and Vice President, Recursion Pharmaceuticals
- Dr Anders Hogner, Associate Director, Medicinal Chemistry, AstraZeneca
- Dr Anne Goupil-Lamy, Science Council Fellow and Principal Field Application Scientist, BIOVIA
- Dr Carl Poelking, Senior Researcher, Computational Chemistry & Informatics, Astex Pharmaceuticals
- Dr Christina Schindler, Associate Director, Head of Computational Drug Design, Merck KGaA
- Dr Christophe Chabbert, Senior Scientist, Discovery Informatics,, Roche Pharma Research and Early Development (pRED)
- Dr Darren Green, Head of Cheminformatics & Data Science, Senior Felllow, GSK
- Dr Francois-Xavier Baludin de Thé, Computational Scientist, Servier Pharmaceuticals
- Dr Gerhard Hessler, Head of Synthetic Molecular Design, Sanofi
- Dr Grégori Gerebtzoff, Director, Pharmacokinetic Sciences (PKS), Biomedical Research, Novartis
- Dr Guglielmo Iozzia, Associate Director - Data Science, ML/AI, Computer Vision, MSD Ireland
- Dr Haruna Iwaoka, Senior Director, Advanced Modeling & Display, Discovery Intelligence, Astellas Pharma Inc.
- Dr Iain Moal,
Scientific Leader, GSK Fellow, Computational Antibody Engineering,
Medical Science & Technology, GSK Research & Development
- Dr James Lumley, Associate Director, Cheminformatics and Data Science, GSK
- Dr Maria Wendt, Global Head of Digital and and Biologics Strategy & innovation, Large Molecule Research, Sanofi
- Dr Martin Akerman, Co-Founder & CTO, Envisagenics
- Dr Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris
- Dr Nadine Schneider, Lead, Generative Chemistry, Biomedical Research, Novartis
- Dr Nicola Richmond, VP of AI, BenevolentAI
- Dr Petrina Kamya, President of Insilico Medicine Canada and Vice President, Head of AI Platforms, Insilico Medicine
- Dr Rabia Khan, Founder & CEO, Serna.bio
- Dr Simone Fulle, Head of Protein Engineering, Novo Nordisk A/S
- Dr Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals
- Dr Yogesh Sabnis, Director, Lead Design, UCB Biopharma srl
- Karl Leswing, Executive Director, Machine Learning, Schrödinger
- Martin Buttenschoen, Research Student, Oxford Protein informatics Group, University of Oxford
- Michael Edmund Beck, Distinguished Science Fellow, Bayer AG
- Philipe Moingeon, Professor, AI and Drug Sciences, Paris-Saclay University and Head of Immuno-Inflammation Portfolio, Servier Pharmaceuticals
- Philipp Lorenz, CTO, Basecamp Research
- Quentin Perron, Co-Founder & CSO, Iktos
The full agenda is not yet available for this event.
Follow this event to receive an alert when the agenda becomes available.
Venue
Courtyard by Marriott Boston Downtown
275 Tremont St, 02116
Boston, MA, USA
